Cohance Downgraded by ICICI Securities Despite Target Price Hike After Q4 Results

Cohance's Q4 and FY26 performance remained under pressure due to continued inventory de-stocking in two large pharma CDMO products, product-specific challenges in the API segment and a delay in the...